January 30, 2008

SpeculatingStocks.com Stock Pick: Geron Corporation (GERN)

Stock Price: $5.15

Geron Corporation is a biopharmaceutical company developing therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes, and HIV/AIDS. The company is developing human embryonic stem cell therapies, including GRNOPC1, which contains oligodendroglial progenitor cells targeted for the treatment of spinal cord injury.

GERN could benefit from the upcoming presidential elections. Greater stem cell funding and support could be on its way creating a more positive environment for GERN to operate.

GERN is one of the more well known stem cell development companies and trading at a market cap of only around $388 million.

GERN has a very strong balance sheet with over $208 million in cash and short-term investments on the balance sheet and no long-term debt and total liabilities of only $12.46 million.

We believe GERN will start living up to its potential. GERN's next catalyst may come from FDA approval for GERN to start clinical trials on a stem cell treatment for spinal cord injuries.